BC
CDTX

Broadfin Capital’s Cidara Therapeutics CDTX Stock Holding History

Broadfin Capital’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-18,791
Closed -$1.5M – 49
2018
Q1 		$1.5M Sell
18,791
-24,079
-56% -$3.29M 0.23% 47
2017
Q4 		$5.83M Buy
42,870
+1,850
+5% +$281K 0.95% 27
2017
Q3 		$6.64M Buy
41,020
+206
+0.5% +$29.3K 0.98% 26
2017
Q2 		$6.12M Buy
40,814
+12,670
+45% +$1.75M 0.74% 34
2017
Q1 		$4.39M Hold
28,144
– – 0.53% 36
2016
Q4 		$5.85M Buy
28,144
+19,800
+237% +$4.11M 0.65% 39
2016
Q3 		$1.91M Hold
8,344
– – 0.17% 66
2016
Q2 		$1.72M Hold
8,344
– – 0.17% 61
2016
Q1 		$2.12M Hold
8,344
– – 0.2% 63
2015
Q4 		$2.86M Hold
8,344
– – 0.18% 77
2015
Q3 		$2.12M Buy
8,344
+844
+11% +$241K 0.12% 82
2015
Q2 		$2.1M Buy
+7,500
New +$2.31M 0.11% 89

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Broadfin Capital's CDTX Position: Q2 2018 in Review

Broadfin Capital sold out of Cidara Therapeutics (CDTX) in Q2 2018, closing a stake of 18,791 shares — an estimated $1.5M sold.

Broadfin Capital first reported a position in CDTX in Q2 2015 and held it in 12 quarters. The position peaked at $6.64M in Q3 2017. 56 funds tracked by Wall St. Rank hold CDTX as of Q2 2018.

  • Broadfin Capital reported no remaining Cidara Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Broadfin Capital sold 18,791 Cidara Therapeutics shares in Q2 2018, an estimated $1.5M.
  • Broadfin Capital first reported a position in Cidara Therapeutics in Q2 2015 and held it in 12 quarters.
  • Broadfin Capital's Cidara Therapeutics position peaked at $6.64M in Q3 2017.
  • 56 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2018.

Based on Broadfin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.